Diphtheria is a serious bacterial infection that, without proper medical care, can be life-threatening, but modern medicine has developed effective ways to fight it and prevent its spread through vaccination and timely treatment.

Fighting a Disease Once Common, Now Rare in Developed Nations

When someone develops diphtheria, the main goals of treatment are to stop the bacterial toxin from causing more damage, eliminate the bacteria from the body, and prevent serious complications that can affect the heart, nerves, and other vital organs. This infection can progress quickly, so doctors focus on starting treatment immediately, even before laboratory tests confirm the diagnosis. The approach to managing diphtheria depends on which part of the body is infected, how severe the symptoms are, and whether the patient has been vaccinated against the disease.^[1][2]

Treatment strategies have evolved significantly over the decades. Before vaccines became widely available in the 1930s, diphtheria was a common and feared childhood disease that claimed many lives. Today, medical societies and health organizations have established standard protocols for treating this infection, based on decades of clinical experience. These guidelines help doctors know exactly what steps to take when a patient presents with symptoms. At the same time, researchers continue to study better ways to manage the disease and its complications, though most current research focuses on prevention through vaccination rather than developing entirely new treatments for active infections.^[4][15]

Standard Treatment Approaches

The cornerstone of diphtheria treatment involves two main components that work together: antibiotics to kill the bacteria and antitoxin to neutralize the poisonous substance the bacteria produce. When doctors suspect diphtheria, especially the respiratory form that affects the throat and airways, they begin treatment right away without waiting for laboratory confirmation. This immediate action is crucial because delays can lead to severe complications or death. Even with prompt treatment, studies show that around 5 to 10 percent of patients may not survive, and this rate can be higher in young children and elderly adults.^[6][10]

For antibiotics, doctors typically prescribe either erythromycin or penicillin. These are the only two antibiotics specifically recommended for diphtheria, even though the bacteria might be sensitive to other drugs. The reason is that these two have been proven effective in real-world clinical situations, not just in laboratory studies. Erythromycin can be given by mouth or through a vein, depending on how sick the patient is. Penicillin is usually given as an injection. The antibiotic treatment typically continues for about two weeks. The purpose of antibiotics is to stop the bacteria from multiplying and producing more toxin, and to prevent the patient from spreading the infection to others. After about 48 hours of antibiotic treatment, most patients are no longer contagious, but they must complete the full course of treatment.^[11][14]

The other critical component is diphtheria antitoxin, which is a special medication made from horse serum. This antitoxin works by attaching to the diphtheria toxin that is circulating in the bloodstream and neutralizing it before it can enter cells and cause damage. The antitoxin can only stop toxin that is still in the blood; once the toxin has entered cells, the antitoxin cannot reverse the damage. This is why early administration is so important. The dose and how it is given (either into a vein or into a muscle) depend on how severe the infection is and where it is located in the body. Before giving antitoxin, doctors must test the patient for allergies to horse serum, because some people can have severe allergic reactions. In the United States, this antitoxin is not readily available in pharmacies but must be obtained directly from the Centers for Disease Control and Prevention through a special emergency protocol.^[3][14]

In severe cases where the thick membrane in the throat blocks breathing, doctors may need to perform emergency procedures to keep the airway open. This might involve inserting a breathing tube through the mouth and throat, or in very serious situations, performing a tracheostomy, which means making an opening in the windpipe through the neck and inserting a tube there. These procedures can be life-saving when the airway is critically narrowed. Patients with severe diphtheria are usually admitted to an intensive care unit where their heart rhythm and breathing can be closely monitored. The toxin can damage the heart muscle, causing irregular heartbeats or heart failure, and it can also damage nerves, leading to paralysis. Doctors watch for these complications and treat them as they arise.^[10][12]

After finishing antibiotic treatment, patients must have follow-up tests to make sure all the bacteria are gone from their body. This is done by taking swabs from the nose and throat and testing them in a laboratory. Two consecutive negative tests, taken 24 hours apart, confirm that the patient is no longer carrying the bacteria. This is important because some people can become carriers, meaning they have bacteria in their body but no symptoms, and they can still spread the infection to others. Additionally, anyone who has had diphtheria needs to complete or start their vaccination series during recovery, because having the disease does not guarantee immunity against future infections.^[11][14]

People who have been in close contact with a diphtheria patient also need treatment, even if they do not have symptoms. Close contacts include family members, people who live in the same household, and anyone who has had frequent close contact with the patient or direct exposure to their respiratory secretions or skin sores. These individuals are given antibiotics as a preventive measure (usually erythromycin or penicillin for about a week) and are monitored for symptoms for 7 to 10 days after their last exposure. They also have their nose and throat swabbed to test for the bacteria. If their vaccinations are not up to date, they receive a booster dose. Health departments typically coordinate these contact tracing and prevention efforts to stop the disease from spreading in the community.^[3][11]

Innovative Approaches and Clinical Research

Because diphtheria has become extremely rare in developed countries like the United States and most of Europe, there is currently very limited active clinical trial research focused on developing new drugs specifically to treat active diphtheria infections. The success of vaccination programs has reduced the disease burden so dramatically that the main research focus remains on improving vaccine coverage and developing better vaccines, rather than on finding new treatments for people who are already sick. Most clinical trials related to diphtheria today involve testing new vaccine formulations or studying the immune response to vaccination in different populations.^[4][15]

The existing treatment approach with antitoxin and antibiotics has been in place for many decades and remains the standard of care endorsed by medical authorities worldwide. The diphtheria antitoxin itself is not a new development; it was first developed in the late 1800s and has been used ever since. While the manufacturing process has been refined over time, the basic principle remains the same: horses are immunized with small amounts of diphtheria toxin, and then antibodies are harvested from their blood to create the antitoxin medicine. This is why the antitoxin is called “horse-derived hyperimmune antiserum.”^[14]

In places where diphtheria outbreaks still occur, such as some areas of Southeast Asia, India, and parts of Africa and South America, the focus is on rapidly deploying existing vaccines and treatments rather than testing experimental therapies. Public health efforts concentrate on strengthening routine immunization programs, ensuring cold chain maintenance for vaccines, and training healthcare workers to recognize and treat cases early. Research in these settings often looks at how to improve vaccine delivery systems, how to reach underserved populations, and how to maintain surveillance systems that can detect outbreaks quickly.^[4][15]

Some research has explored understanding the molecular mechanisms of how the diphtheria toxin causes damage at the cellular level. Scientists have studied how the toxin enters cells and interferes with protein production, which kills the cells. This basic research helps us understand why the disease is so dangerous and could theoretically lead to new treatment ideas in the future, but currently, these are laboratory studies rather than clinical trials testing new medicines in patients. Understanding how toxigenic strains of the bacteria (those that produce toxin) differ from non-toxigenic strains has also been important for diagnostic purposes and for understanding disease transmission patterns.^[7][13]

One area where some development work continues is in making antitoxin that is not derived from horses, which would eliminate the risk of allergic reactions to horse serum. However, this remains largely in research phases and has not replaced the standard horse-derived antitoxin in clinical practice. Similarly, there has been interest in developing rapid diagnostic tests that can quickly confirm whether a patient has toxin-producing bacteria, which would help doctors make faster treatment decisions. Currently, confirming diphtheria in the laboratory takes several days because the bacteria must be grown in culture and then tested to see if they produce toxin.^[3]

Because there are no major ongoing clinical trials testing novel drugs for diphtheria treatment, patients are treated according to well-established protocols using the medications that have been proven effective over many years. The focus of medical research has appropriately shifted to prevention, because vaccination is far more effective at saving lives than treating the disease after someone becomes infected. Global health organizations like the World Health Organization continue to work on strategies to improve vaccine coverage worldwide, particularly in areas where immunization rates have dropped due to conflicts, poverty, or disruptions to health systems. The COVID-19 pandemic, for example, caused disruptions to routine childhood vaccination programs in many countries, which has raised concerns about possible increases in diphtheria cases in areas with low vaccine coverage.^[4][15]

Most Common Treatment Methods

• Antibiotic Therapy
  • Erythromycin administered orally or intravenously to kill diphtheria bacteria and stop toxin production
  • Penicillin given by injection as an alternative antibiotic option
  • Treatment typically lasts for two weeks to ensure complete eradication of bacteria
  • Makes patients non-contagious after approximately 48 hours of treatment
• Antitoxin Administration
  • Horse-derived diphtheria antitoxin to neutralize circulating toxin in the bloodstream
  • Administered intravenously or intramuscularly depending on disease severity
  • Most effective when given early, before toxin enters cells and causes damage
  • Requires allergy testing before administration due to horse serum content
  • Must be obtained from Centers for Disease Control and Prevention in the United States
• Supportive Care and Monitoring
  • Intensive care unit admission for severe cases to monitor heart rhythm and breathing
  • Emergency airway management including intubation or tracheostomy when breathing is compromised
  • Cardiac monitoring and treatment for heart complications including myocarditis
  • Respiratory support with mechanical ventilation if needed
  • Isolation precautions to prevent disease spread to others
• Preventive Treatment for Contacts
  • Antibiotic prophylaxis with erythromycin or penicillin for all close contacts
  • Throat and nasal cultures to detect carriers among contacts
  • Vaccination booster doses for contacts not up to date with immunizations
  • Monitoring of contacts for symptom development for 7 to 10 days
• Post-Treatment Follow-Up
  • Two consecutive negative bacterial cultures 24 hours apart to confirm elimination of bacteria
  • Vaccination during convalescence period since infection does not guarantee immunity
  • Monitoring for late complications affecting heart and nervous system